In order to evaluate substantial clinical improvement over currently available treatments to meet the transitional pass-through payment criterion at 419.66(c)(2), we stated that we consider supporting evidence, preferably published peer-reviewed clinical trials, that demonstrates improved clinical outcomes, such as reduction in mortality, complications, subsequent interventions, future hospitalizations, recovery time, pain, or a more rapid beneficial resolution of the disease process comparing the nominated device to the standard of care (88 FR 81733)
We proposed to calculate the default ratios for CY 2026 using the most recent cost report data
Loosey-goosey tissues (as I sometimes describe it to patients) need something to help them reorganize
We utilize High-Performance Liquid Chromatography (HPLC) coupled with Mass Spectrometry (MS) to confirm an absolute chemical purity profile of 99% or greater for the peptide components, alongside strict gas chromatography or nuclear magnetic resonance (NMR) validation for the integrated lipids and triglycerides